CY1107706T1 - Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea) - Google Patents
Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea)Info
- Publication number
- CY1107706T1 CY1107706T1 CY20071101013T CY071101013T CY1107706T1 CY 1107706 T1 CY1107706 T1 CY 1107706T1 CY 20071101013 T CY20071101013 T CY 20071101013T CY 071101013 T CY071101013 T CY 071101013T CY 1107706 T1 CY1107706 T1 CY 1107706T1
- Authority
- CY
- Cyprus
- Prior art keywords
- care
- cea
- peptide antagonists
- embryonal antigen
- antigen
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 abstract 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 abstract 4
- 239000000556 agonist Substances 0.000 abstract 2
- 241001368098 Capis Species 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Pregnancy & Childbirth (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Η παρούσα εφεύρεση αφορά την παρασκευή και χρήση πεπτιδίων που δρουν ως αγωνιστές και ανταγωνιστές του ανθρώπινου καρκινοεμβρυονικού αντιγόνου (CEA). Αποκαλύπτονται αγωνιστές του CEA πεπτιδίου, CAPI και καταδεικνύεται η χρησιμότητα αυτών στην αύξηση άνοσων αποκρίσεων έναντι CEA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6158997P | 1997-10-10 | 1997-10-10 | |
EP04011673A EP1447414B1 (en) | 1997-10-10 | 1998-09-22 | Antagonist peptides of carcinoembryonic antigen (CEA) |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1107706T1 true CY1107706T1 (el) | 2013-04-18 |
Family
ID=22036775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071101013T CY1107706T1 (el) | 1997-10-10 | 2007-07-30 | Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea) |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1017810B1 (el) |
JP (1) | JP4291508B2 (el) |
AT (2) | ATE364048T1 (el) |
AU (1) | AU745863B2 (el) |
CA (1) | CA2308127C (el) |
CY (1) | CY1107706T1 (el) |
DE (2) | DE69824023T2 (el) |
DK (1) | DK1447414T3 (el) |
ES (2) | ES2286530T3 (el) |
PT (1) | PT1447414E (el) |
WO (1) | WO1999019478A1 (el) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9923309D0 (en) * | 1999-10-01 | 1999-12-08 | Glaxo Group Ltd | Assay |
ES2447115T3 (es) * | 1999-10-11 | 2014-03-11 | Institut Pasteur | Vectores para la preparación de composiciones inmunoterapéuticas |
AU1013701A (en) * | 1999-10-22 | 2001-05-08 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
EP1305414A2 (en) * | 2000-07-31 | 2003-05-02 | Aventis Pasteur Limited | Modified cea and uses thereof |
EP1467751A2 (en) * | 2002-01-17 | 2004-10-20 | Pharmexa A/S | Immunogenic cea |
US6949629B2 (en) | 2002-03-13 | 2005-09-27 | Aspenbio, Inc. | Methods for purifying selected CEA family member proteins |
EP1567014B1 (en) * | 2002-12-04 | 2011-09-28 | Baylor Research Institute | Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors |
EP1581174B1 (en) * | 2002-12-16 | 2018-04-25 | GlobeImmune, Inc. | Yeast-based vaccines as immunotherapy |
WO2005114444A1 (en) | 2004-04-30 | 2005-12-01 | America Online, Inc. | Network configuration management |
WO2009006479A2 (en) | 2007-07-02 | 2009-01-08 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
KR101167392B1 (ko) | 2007-07-27 | 2012-07-19 | 이매틱스 바이오테크놀로지스 게엠베하 | 종양 관련 펩티드의 조성물 및 관련된 항암 백신 |
US9249187B2 (en) | 2009-01-28 | 2016-02-02 | Epimmune Inc. | Pan-DR binding polypeptides and uses thereof |
JP5759980B2 (ja) | 2009-04-17 | 2015-08-05 | グローブイミューン,インコーポレイテッド | 癌および感染症に対する免疫療法組成物の組み合わせ |
WO2014031178A1 (en) | 2012-08-24 | 2014-02-27 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
US10695417B2 (en) | 2015-01-09 | 2020-06-30 | Etubics Corporation | Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein |
CN113456812A (zh) | 2015-01-09 | 2021-10-01 | 埃图比克斯公司 | 用于联合免疫治疗的方法和组合物 |
EP3286213B1 (en) | 2015-04-20 | 2021-08-04 | Etubics Corporation | Methods and compositions for combination immunotherapy |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992019266A1 (en) * | 1991-05-06 | 1992-11-12 | The United States Of America, As Represented By The Department Of Health And Human Services | Recombinant virus expressing carcinoembryonic antigen and methods of use thereof |
US6001349A (en) * | 1995-02-22 | 1999-12-14 | Therion Biologics Corporation | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
-
1998
- 1998-09-22 JP JP2000516030A patent/JP4291508B2/ja not_active Expired - Lifetime
- 1998-09-22 WO PCT/US1998/019794 patent/WO1999019478A1/en active IP Right Grant
- 1998-09-22 ES ES04011673T patent/ES2286530T3/es not_active Expired - Lifetime
- 1998-09-22 DE DE69824023T patent/DE69824023T2/de not_active Expired - Lifetime
- 1998-09-22 DK DK04011673T patent/DK1447414T3/da active
- 1998-09-22 DE DE69837896T patent/DE69837896T2/de not_active Expired - Fee Related
- 1998-09-22 CA CA2308127A patent/CA2308127C/en not_active Expired - Lifetime
- 1998-09-22 PT PT04011673T patent/PT1447414E/pt unknown
- 1998-09-22 EP EP98948429A patent/EP1017810B1/en not_active Expired - Lifetime
- 1998-09-22 AT AT04011673T patent/ATE364048T1/de active
- 1998-09-22 AU AU95004/98A patent/AU745863B2/en not_active Expired
- 1998-09-22 AT AT98948429T patent/ATE267213T1/de not_active IP Right Cessation
- 1998-09-22 ES ES98948429T patent/ES2217585T3/es not_active Expired - Lifetime
-
2007
- 2007-07-30 CY CY20071101013T patent/CY1107706T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2308127C (en) | 2011-03-22 |
DE69824023T2 (de) | 2005-05-12 |
PT1447414E (pt) | 2007-07-18 |
EP1017810A1 (en) | 2000-07-12 |
JP4291508B2 (ja) | 2009-07-08 |
ATE364048T1 (de) | 2007-06-15 |
DE69837896D1 (de) | 2007-07-19 |
CA2308127A1 (en) | 1999-04-22 |
AU9500498A (en) | 1999-05-03 |
EP1017810B1 (en) | 2004-05-19 |
DE69837896T2 (de) | 2008-02-14 |
ES2217585T3 (es) | 2004-11-01 |
DE69824023D1 (de) | 2004-06-24 |
ATE267213T1 (de) | 2004-06-15 |
JP2002500002A (ja) | 2002-01-08 |
ES2286530T3 (es) | 2007-12-01 |
WO1999019478A1 (en) | 1999-04-22 |
AU745863B2 (en) | 2002-04-11 |
DK1447414T3 (da) | 2007-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107706T1 (el) | Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea) | |
ATE272070T1 (de) | Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen | |
TR199900666T2 (xx) | �nsan paratormonu ile ilgili peptidlere kar�� antikor. | |
EA199800946A1 (ru) | Концентрированный препарат антител | |
NZ503763A (en) | Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use | |
TR200100936T2 (tr) | Terapötik aşılama | |
HUP0302532A2 (hu) | Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások | |
PT1171143E (pt) | Extracto peptidico de tremoco e composicao farmaceutica ou cosmetica ou nutraceutica compreendendo o referido extracto | |
MX9707021A (es) | Receptor de il-7. | |
ES2174837T3 (es) | Conjugados de saponina-antigeno y su utilizacion. | |
DK0719340T3 (da) | Klonet glutaminsyre-decarboxylase | |
DK1152012T3 (da) | Tuberkulosevacciner | |
GB2255093A (en) | Hiv-1 core protein fragments | |
WO2002064057A3 (en) | Use of cell penetrating peptides to generate antitumor immunity | |
BR9509172A (pt) | Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica | |
BR9709958A (pt) | Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso | |
ATE442439T1 (de) | Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren | |
ATE220718T1 (de) | Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten | |
DE69933875D1 (de) | Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt. | |
DE60114590D1 (de) | Peptide, die cea ("carcinoembryonic antigen") binden | |
EP1447414A3 (en) | Agonist and antagonist peptides of carcinoembryonic antigen (CEA) | |
FI953257A0 (fi) | Rekombinanttinen ihmisen prostaspesifinen antigeenRekombinanttinen ihmisen prostaspesifinen antigeeni ja sen käytöt i ja sen käytöt | |
GR3036057T3 (en) | Urogenital carcinoma tlp complex peptides and antibodies thereof | |
ZA98587B (en) | A novel antigen from P. aeruginosa, and its use in medicine. | |
BR0016740A (pt) | Antìgenos de esporozoìto de cryptosporidium |